Lorazepam - Revision history

MDElliottMD: parser-claude: Lorazepam MedTemplate refill, Top 300 stub upgrade

2026-05-23T06:56:43Z

parser-claude: Lorazepam MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 06:56, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Lorazepam		\| generic = Lorazepam
	\| brand = Ativan		\| brand = Ativan (oral, injectable), Loreev XR
	\| structure =		\| structure =
	\| classes = Benzodiazepine, Anxiolytic		\| classes = [[:Category:Benzodiazepines\|Benzodiazepine]], [[:Category:Anxiolytics\|Anxiolytic]], [[:Category:Schedule IV controlled substances\|Schedule IV controlled substance]]
	\| ~~mechanism = GABAA positive allosteric modulator~~		\| uses = <vote slug="anxiety-disorders-broad-use">Anxiety disorders (FDA)</vote>, <vote slug="preoperative-sedation-use">Preoperative sedation (FDA, IV)</vote>, <vote slug="status-epilepticus-use">Status epilepticus (FDA, IV; first-line per current guidelines)</vote>, <vote slug="alcohol-withdrawal-use">Alcohol withdrawal (off-label, often first-line in hepatic impairment)</vote>, <vote slug="agitation-acute-use">Acute agitation (off-label, IM)</vote>, <vote slug="chemotherapy-induced-nausea-use">Chemotherapy-induced nausea (off-label adjunct)</vote>
	\| uses =		\| starting_dose = Anxiety: 0.5-1 mg PO BID-TID. Insomnia: 1-2 mg PO at bedtime. Status epilepticus: 4 mg IV (adult), repeat after 5-10 minutes if needed. Acute agitation: 1-2 mg IM
	\| starting_dose =		\| preparations = Tablets 0.5, 1, 2 mg; oral concentrate 2 mg/mL; injection 2 mg/mL and 4 mg/mL; Loreev XR capsules 1, 2, 3 mg
	\| preparations =		\| fda_max = 10 mg/day (anxiety, oral)
	\| fda_max =		\| pill_id =
	\| routes =		\| routes = Oral, intramuscular, intravenous
	\| onset =		\| onset = 30-60 minutes (oral); 5 minutes (IV); 15-30 minutes (IM)
	\| duration =		\| duration = 6-8 hours
	\| halflife =		\| halflife = 12-15 hours (intermediate); '''no active metabolites''' (key clinical feature)<ref name="ativan-label">FDA Prescribing Information, Ativan (lorazepam), Bausch/Pfizer, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017794s044lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ~90% (oral)<ref name="ativan-label" />
	~~\| pregnancy~~ =		\| pregnancy = Some signal for cleft lip/palate with first-trimester exposure (debated); neonatal sedation and withdrawal with third-trimester exposure.{{citation needed}}
	~~\| legal~~ =		\| legal = [[USLegal:Schedule IV\|Schedule IV controlled substance]] in US. Carries the benzodiazepine class '''Boxed Warning''' for risk of fatal respiratory depression, coma, and death when combined with opioids<ref name="ativan-label" />
	\| ~~intro =~~		\| mechanism = <vote slug="lorazepam-mech-claim">Positive allosteric modulator of the GABA-A receptor at the benzodiazepine binding site (α-γ subunit interface), enhancing chloride ion conductance and consequent neuronal inhibition. The intermediate half-life sits between short-acting alprazolam and long-acting diazepam/clonazepam, making lorazepam a clinically versatile choice.</vote> Metabolized by '''glucuronidation rather than CYP''', so unlike alprazolam and diazepam, lorazepam has minimal CYP-mediated interactions, and the lack of active metabolites makes it the preferred benzodiazepine in elderly patients and in hepatic impairment. Tolerance, dependence, and significant withdrawal syndrome on abrupt discontinuation; slow taper essential after extended use<ref name="ativan-label" />.
	~~\| pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	\| ~~indications~~ =
	\| ~~dosing~~ =
	\| ~~effects =~~
	~~\| interactions~~ = ~~<pharmaInteractions~~/>
	\| ~~pregnancy_details =~~
	~~\| monitoring~~ =
	~~\| counseling~~ =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

			== References ==
			<references />

	[[Category:Benzodiazepines]]		[[Category:Benzodiazepines]]
	[[Category:Anxiolytics]]		[[Category:Anxiolytics]]
	[[Category:~~GABAA Positive Allosteric Modulators (General)]]~~		[[Category:Schedule IV controlled substances]]
	~~[[Category:GABAergics~~]]

MDElliottMD: Tier 2 taxonomy consolidation: remove retired Category:Anxiolytics & Sedative-Hypnotics

2026-05-21T17:44:50Z

Tier 2 taxonomy consolidation: remove retired Category:Anxiolytics & Sedative-Hypnotics

← Older revision		Revision as of 17:44, 21 May 2026
Line 32:		Line 32:


	~~[[Category:Anxiolytics & Sedative-Hypnotics]]~~
	[[Category:Benzodiazepines]]		[[Category:Benzodiazepines]]
	[[Category:Anxiolytics]]		[[Category:Anxiolytics]]
	[[Category:GABAA Positive Allosteric Modulators (General)]]		[[Category:GABAA Positive Allosteric Modulators (General)]]
	[[Category:GABAergics]]		[[Category:GABAergics]]

MDElliottMD: Comprehensive categorization: +GABAA Positive Allosteric Modulators (General), GABAergics

2026-05-15T18:42:10Z

Comprehensive categorization: +GABAA Positive Allosteric Modulators (General), GABAergics

← Older revision		Revision as of 18:42, 15 May 2026
Line 35:		Line 35:
	[[Category:Benzodiazepines]]		[[Category:Benzodiazepines]]
	[[Category:Anxiolytics]]		[[Category:Anxiolytics]]
			[[Category:GABAA Positive Allosteric Modulators (General)]]
			[[Category:GABAergics]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:52Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Anxiolytics & Sedative-Hypnotics]]
			[[Category:Benzodiazepines]]
	[[Category:Anxiolytics]]		[[Category:Anxiolytics]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:57Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:39Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:41Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Anxiolytics]]		[[Category:Anxiolytics]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Lorazepam
+| generic            = Lorazepam
-| brand             = Ativan
+| brand              = Ativan
-| classes           = Benzodiazepine, Anxiolytic
+| structure          =
-| mechanism         = GABAA positive allosteric modulator
+| classes            = Benzodiazepine, Anxiolytic
 }}
 [[Category:Anxiolytics]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Lorazepam
| brand = Ativan
| classes = Benzodiazepine, Anxiolytic
| mechanism = GABAA positive allosteric modulator
}}
[[Category:Anxiolytics]]